Skip to main content
Industry News
Sitagliptin tied to lower mortality in T2D, COVID-19

A study in Diabetes Care found that patients with type 2 diabetes and COVID-19 who took a combination of sitagliptin and insulin had an 18% mortality rate, compared with a 37% mortality rate among those who only took insulin. The findings also revealed that the group who took both sitagliptin and insulin had lower odds of requiring mechanical ventilation and intensive care, and were less likely to have a worsening of clinical outcomes, compared with the group who only took insulin.

Full Story: